http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
NovaBay Pharma (NBY) CEO Issues Letter to Stockholders
-
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
-
NovaBay Pharmaceuticals to Present at the Virtual Life Sciences Investor Forum
-
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor’s Eczema Balm on Return QVC® Appearance
-
NovaBay Pharma (NBY) Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million
-
NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million
-
NovaBay Pharmaceuticals Reports Second Quarter 2022 Financial Results
-
NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11
-
NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova® Lid and Lash Spray for Lash Extensions
-
NovaBay Pharmaceuticals’ DERMAdoctor Products Now Available at Target.com and Urbanoutfitters.com
-
NovaBay Pharma (NBY) Reports Record Avenova Sales During Amazon’s Prime Day Event
-
NovaBay Pharmaceuticals Reports Record Avenova® Sales During Amazon’s Prime Day Event
-
NovaBay Pharmaceuticals’ DERMAdoctor Products to be Featured at Leading B2B Beauty Trade Show Cosmoprof North America
-
NovaBay Pharmaceuticals Reports First Quarter 2022 Financial Results
-
NovaBay Pharma (NBY) Expands DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations
-
NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations
-
NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12
-
NovaBay Pharma (NBY) CEO Issues Letter to Stockholders
-
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
-
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor’s Eczema Treatment
-
NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line
-
NovaBay Pharmaceuticals Reports 2021 Fourth Quarter and Full Year Financial Results
-
NovaBay Pharmaceuticals to Hold 2021 Fourth Quarter and Full Year Conference Call on March 29
-
NovaBay Pharma's (NBY) DERMAdoctor Launches New HA Serum to Expand Calm Cool + Corrected Product Line
-
DERMAdoctor Launches New HA Serum to Expand Calm Cool + Corrected Product Line
-
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC® On-Air Guest
-
NovaBay Pharma (NBY) Partners with Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China
-
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China
-
NovaBay Pharma (NBY) Announces Board Changes
-
NovaBay Pharmaceuticals Announces Changes to Its Board of Directors
-
NovaBay Pharma (NBY) Announced Donation of 2.5M KN95 Masks
-
NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks
-
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
-
NovaBay Pharma (NBY) Launches Lubricating Eye Drops
-
NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms
-
NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
-
NovaBay Pharmaceuticals Holds Special Meeting of Stockholders
-
DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance
-
NovaBay Pharma (NBY) CEO's Letter to Stockholders
-
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
-
NovaBay Pharmaceuticals Reports Third Quarter 2021 Financial Results
-
NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
-
NovaBay Pharmaceuticals Closes $15.0 Million Private Placement
-
NovaBay Pharma (NBY) Prices 15,000 Share Preferred Private Placement at $1,000/sh
-
NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement
-
NovaBay Pharmaceuticals to Hold Conference Call and Webcast With Slide Presentation Today to Discuss Acquisition of DERMAdoctor
-
NovaBay Pharma (NBY) to Acquire DERMAdoctor for $15M
-
NovaBay Pharmaceuticals Signs Agreement to Acquire DERMAdoctor
-
NovaBay Pharmaceuticals to Present at the H.C. Wainwright 23nd Annual Global Investment Conference
-
NovaBay Pharmaceuticals Reports Second Quarter 2021 Financial Results

